Celldex Therapeutics

Blue Sky BioServices, founded in 2003 to serve the Boston area life sciences research hub, is the leading Contract Research Organization (CRO) providing R&D based Gene through Screen services for biotech and pharma companies from startups to established leaders in the field. Our customers enhance the quality and speed of their research by partnering with Blue Sky to receive world class services including; gene synthesis and bulk plasmid preparations, antibody cloning, scale-up production of recombinant proteins in multiple cell lines including mammalian, insect, bacterial and yeast, as well as antibody/protein purification and robust, rapid assay services such as cytotoxicity and qPCR, MSD. Our Assay team can support many commercially available screening technology in 96 and 384-well formats (fluorescent, colorimetric, etc.). Ultimately, we want to run YOUR assay, YOUR way. We will build out additional capabilities and capacity to support your screening workflow.

Blue Sky differentiates itself with its team of experienced scientists, leading edge process technology, and state-of-the-art laboratory facilities. Our commitment to scientific expertise and value has transformed the company into a center of excellence with unmatched quality and turnaround times.

We are motivated by ensuring our customers have an excellent experience working with Blue Sky. We do that by delivering projects on time, with high quality, at competitive prices, led by our team of highly skilled, energetic and collaborative scientists.

Comparative Biosciences Inc., a premier preclinical contract research organization (CRO) committed, for the last 20 years, to providing expert high-quality contract research services to all sectors of the biomedical community. Extensive experience in the biotechnology and pharmaceutical industries provides our staff with an exceptional track record in preclinical research and drug development capabilities.

Our on-site histology laboratory offers routine histopathology, special stains, immunohistochemistry (IHC), plastics, GLP antibody tissue cross reactivity (TCR), and histomorphometry services with quick turn around times. We also have the benefit of having an on site board-certified pathologist for evaluation and reporting of all the histology work done here.

F-star is a leading clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients with cancer greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific antibody (mAb²™) format, F-star is generating best-in-class drug candidates with broad therapeutic index and monoclonal antibody-like manufacturability. Building on the combined expertise of its world-class management team and scientific leadership, F-star is poised to deliver the next breakthrough immunotherapies for patients with cancer.

Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 300,000 customers from over 160 countries and regions around the world have used GenScript’s premier, convenient, and reliable products and services. GenScript currently has more than 3000 employees globally, 33% of whom hold master’s and/or Ph.D. degrees. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis and bioinformatics, including more than 100 patents and over 270 patent applications. As of January 2019, GenScript's products and services have been cited by 36,500 scientific papers worldwide. GenScript is committed to striving towards its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.

Hangzhou AllTest Biotech Co., Ltd is located in 550#，Yinhai Street, Baiyang District, Hangzhou Economic-Technological Development Area, the company registered capital of 15 million RMB. The company’s total construction area is about 3200 M2. The company holds strong ability of scientific research and innovative technology. AllTest Biotech leads the development frontier of biological technologies such as monoclonal antibody-colloidal gold and latex technique, gene engineering, compound antigen and immunoassay.

AllTest Biotech is thriving on design, development, manufacturing and sales of the lateral flow rapid IVD products and food safety test product. The product is broadly recognized in the international market for its rapid, convenience and accurateness. AllTest Biotech will strive to become the leader and pioneer in the diagnostic industry field of China and the world.